Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Wenjing Guo, Yizhou Zheng, Sizhou Feng
The Omicron variant of SARS-CoV-2 has rapidly become the dominant strain worldwide due to its high transmissibility, although it appears to be less pathogenic than previous strains. However, individuals with hematological malignancy (HM) and COVID-19 remain susceptible to severe infection and mortality, especially those with chronic lymphocytic leukemia (CLL) and those undergoing chimeric antigen receptor T-cell (CAR-T) treatment. Hematologists should thoroughly assess the severity of the patient's hematological disease and the potential risk of SARS-CoV-2 infection before initiating chemotherapy or immunosuppressive treatment...
2023: Frontiers in Cellular and Infection Microbiology
#22
JOURNAL ARTICLE
Oktawia Sośnia, Katarzyna Pruszczyk, Michał Danecki, Ewa Wąsik-Szczepanek, Jagoda Tryc-Szponder, Elżbieta Iskierka-Jażdżewska, Alan Majeranowski, Helena Krzemień, Łukasz Bołkun, Ewa Paszkiewicz-Kozik, Joanna Drozd-Sokołowska, Jacek Kwiatkowski, Dominika Wiśniewska-Organek, Monika Prochorec-Sobieszek, Anna Szumera-Ciećkiewicz, Bożena Budziszewska, Krzysztof Jamroziak, Iwona Hus, Ewa Lech-Marańda, Bartosz Puła
Richter transformation (RT) is defined as developing an aggressive lymphoma in 2-10% of patients suffering from chronic lymphocytic leukemia (CLL). So far, no complex analysis of RT demographics and treatment outcomes has been performed in Poland. Thus, the retrospective analysis of 124 patients with RT from Polish hematology centers was designed. Ninety-nine patients with diffuse large B-cell lymphoma (DLBCL-RT) were identified. The median overall survival (OS) for DLBCL-RT was 17.3 months, while for Hodgkin lymphoma (HL-RT)-21...
February 2024: Leukemia & Lymphoma
#23
REVIEW
Ifeyinwa E Obiorah, Kalpana D Upadhyaya, Katherine R Calvo
Molecular and sequencing advances have led to substantial breakthroughs in the discovery of new genes and inherited mutations associated with increased risk of developing myeloid malignancies. Many of the same germline mutated genes are also drivers of malignancy in sporadic cancer. Recognition of myeloid malignancy associated with germline mutations is essential for proper therapy, disease surveillance, informing related donor selection for hematopoietic stem cell transplantation, and genetic counseling of the patient and affected family members...
December 2023: Clinics in Laboratory Medicine
#24
JOURNAL ARTICLE
Eunhee Lee, Shinai Lee, Sumyeong Park, Yong-Gyu Son, Jiseon Yoo, Youngil Koh, Dong-Yeop Shin, Yangmi Lim, Jonghwa Won
BACKGROUND: Acute myeloid leukemia (AML) is a type of leukemia in adults with a high mortality rate and poor prognosis. Although targeted therapeutics, chemotherapy, and hematopoietic stem cell transplantation can improve the prognosis, the recurrence rate is still high, with a 5-year survival rate of approximately 40%. This study aimed to develop an IgG-based asymmetric bispecific antibody that targets CLL-1 and CD3 for treating AML. METHODS: ABL602 candidates were compared in terms of binding activity, T-cell activation, and tumor-killing activities...
October 2023: Journal for Immunotherapy of Cancer
#25
JOURNAL ARTICLE
Ludmila Stepanovna Zubarovskaya, Ivan Sergeevich Moiseev, Maria Dmidrievna Vladovskaya, Natalia Borisovna Mikhailova, Elena Vladislavovna Morozova, Tatyana Alexandrovna Bykova, Yulia Yurievna Vlasova, Olesya Vladimirovna Paina, Ilya Viktorovich Kazantsev, Olga Alexandrovna Slesarchuk, Anna Gennadyevna Smirnova, Anna Alekseevna Osipova, Liliya Vladimirovna Stelmakh, Alexey Yurievich Polushin, Oleg Valerievich Goloshchapov, Maxim Pavlovich Bogomolny, Maria Arkadievna Estrina, Marina Olegovna Popova, Maxim Anatolievich Kucher, Alisa Georgievna Volkova, Alexander Leonidovich Alyansky, Dmitrii Eduardovich Pevtcov, Natalia Evgenievna Ivanova, Elena Vitalievna Babenko, Nikolai Nikolaevich Mamaev, Tatiana Leonidovna Gindina, Alina Alexandrovna Vitrishchak, Alexei Borisovich Chukhlovin, Elena Vladimirovna Semenova, Sergei Nicolaevich Bondarenko, Alexander Dmitrievich Kulagin, Boris Vladimirovich Afanasyev
In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4-0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010-2014 vs. 38% in 2015-2022). An improvement in EFS after alloHCT over time was observed (HR 0...
September 28, 2023: Cancers
#26
JOURNAL ARTICLE
Concepción Boqué, Silvia Sánchez-Ramón, Raúl Córdoba, Carol Moreno, Elena Cabezudo
A Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary immunodeficiencies (SID) in the management of oncohematological patients. There was 100% agreement on the need to have available guidelines for the management of immunodeficiency in hematological patients; to perform a baseline immunological evaluation in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), lymphoma and hematopoietic stem cell transplantation (HSCT) recipients; and to quantify serum IgG, IgA and IgM levels when SID is suspected...
October 4, 2023: Journal of Clinical Medicine
#27
Sourabh Goyal, Angela Khidhir, Matthew D Burwinkel
Cardiotoxicity linked with hematopoietic stem cell transplantation (HSCT) is a well-described phenomenon associated with an increased mortality risk; however, the majority of cardiac events present over 100 days following transfusion and are often attributed to graft-versus-host disease or pre-treatment conditioning by chemotherapy with or without radiation therapy. Here, we present the case of a 60-year-old female with a medical history of chronic lymphocytic leukemia complicated by a myelodysplastic syndrome that progressed to acute myeloid leukemia who developed chest pain immediately following an allogeneic HSCT...
September 2023: Curēus
#28
REVIEW
Ofrat Beyar Katz, Dana Yehudai-Ofir, Tsila Zuckerman
BACKGROUND: Chronic lymphocytic leukemia (CLL) is a heterogeneous B-cell malignancy, affecting mainly older adults. Despite the recent introduction of multiple targeted agents, CLL remains an incurable disease. Cellular therapy is a promptly evolving area that has developed over the last decades from such standard of care as hematopoietic cell transplantation (HCT) to the novel treatment modalities employing genetically engineered immune cells. SUMMARY: Tailoring the proper treatment for each patient is warranted and should take into account the disease biology, patient characteristics and the available treatment modalities...
October 9, 2023: Acta Haematologica
#29
JOURNAL ARTICLE
Natasha Malik, Jodie Hay, Hassan N B Almuhanna, Karen M Dunn, Jamie Lees, Jennifer Cassels, Jiatian Li, Rinako Nakagawa, Owen J Sansom, Alison M Michie
Targeted deletion of Raptor, a component of mechanistic target of rapamycin complex 1 (mTORC1), reveals an essential role for mTORC1 in initiation/maintenance of leukemia in a CLL model, resulting from a failure for haemopoietic stem/progenitor cells (HSPCs) to commit to the B cell lineage. Induction of Raptor-deficiency in NSG mice transplanted with Mx1-Raptor CLL progenitor cells (PKCα-KR-transduced HSPCs) after disease establishment revealed a reduction in CLL-like disease load and a significant increase in survival in the mice...
September 29, 2023: Leukemia
#30
JOURNAL ARTICLE
R Xu, S Li, H X Liu, D L Wei, Y Jiang, J J Wang, S S Liu, C Wang, J Zhu
Objective: To evaluate the clinical outcomes and safety of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using a conditioning regimen based on total body irradiation (TBI) and rabbit anti-human thymocyte globulin (rATG) in the management of chemotherapy-resistant advanced peripheral T-cell lymphoma (PTCL) . Methods: Clinical data of 11 patients with chemotherapy-resistant advanced PTCL who underwent haplo-HSCT with a TBI+rATG-based conditioning regimen at the Department of Hematology, Shanghai Liquan Hospital and Shanghai Zhaxin Integrated Traditional Chinese and Western Medicine Hospital, from September 2019 to December 2022 were retrospectively analyzed...
July 14, 2023: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
#31
JOURNAL ARTICLE
Ming-Hsin Hou, Chih-Ying Lee, Cheng-Yin Ho, Ting-Yen Yu, Giun-Yi Hung, Fang-Liang Huang, Tzeon-Jye Chiou, Chun-Yu Liu, Hsiu-Ju Yen
BACKGROUND: Donor lymphocyte infusion (DLI) is effective for managing patients with hematologic malignancies after allogeneic hematopoietic stem cell transplant (HSCT). However, few studies have explored its optimal use in pediatric populations. Herein, we report our single-center experiences of DLI and factors for predicting its outcomes. METHODS: This retrospective study included pediatric patients who had received DLI (between June 1998 and December 2022) after allogeneic HSCT...
September 12, 2023: Journal of the Chinese Medical Association: JCMA
#32
JOURNAL ARTICLE
Kenneth Tham, Stacy Prelewicz, Sara deHoll, Deborah M Stephens, Carlos A Gomez
DISCLAIMER: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE: Ibrutinib is a Bruton's tyrosine kinase inhibitor used to treat multiple hematologic malignancies and graft-versus-host disease...
September 7, 2023: American Journal of Health-system Pharmacy: AJHP
#33
JOURNAL ARTICLE
Shan-Shan Qi, Zhi Chen, Yu Du, Ming Sun, Zhuo Wang, Fei Long, Linlin Luo, Hao Xiong
BACKGROUND: Post-transplant cyclophosphamide (PTCy) has been recommended for prevention of graft-versus-host disease (GvHD) following haploidentical hematopoietic cell transplantation (haplo-HCT) for treatment of malignant blood diseases, but disease relapse remains a problem. Although donor lymphocyte infusion (DLI) is reported to be effective for treating post-transplantation relapse, the efficacy and safety of prophylactic-DLI (pro-DLI) post haplo-HCT, and PTCy in pediatric patients with hematological malignancies is unknown...
November 2023: Pediatric Blood & Cancer
#34
REVIEW
Ilana Levy Yurkovski, Tamar Tadmor
BACKGROUND: Tremendous developments in the field of chronic lymphocytic leukemia (CLL) in recent years have led to a revolutionary change in the treatment approach, which today is based on targeted treatments with a good response and optimal prognosis. Nevertheless, CLL can present or progress to "accelerated CLL" (A-CLL) or to "Richter transformation" (RT) and these two entities have a more aggressive course and are still characterized by challenges in the fields of diagnosis and therapy...
2024: Acta Haematologica
#35
REVIEW
Muhlis Cem Ar, Riad El Fakih, Saule Gabbassova, Ahmad Alhuraiji, Fady Nasr, Ahmad Alsaeed, Nilgun Sayinalp, Mahmoud Marashi
Secondary immunodeficiency (SID) can occur as a result of multiple factors, including hematological malignancies, hematopoietic stem cell transplantation (HSCT), immunosuppressive treatment, biologics, and anti-inflammatory drugs. SID includes disorders resulting from impairment of both cellular and humoral immunity. This review focuses on the current risk factors, implications, and challenges in managing SID patients with impaired humoral immunity, which includes quantitative (hypogammaglobulinemia) and/or functional antibody and B-cell deficiencies specifically related to hematological malignancies and post-HSCT...
July 27, 2023: Leukemia Research
#36
JOURNAL ARTICLE
Aysun Şentürk Yikilmaz, Şule Mine Bakanay, Duygu Nurdan Avcı, Sema Akinci, Mesude Falay, Gülsüm Özet, İmdat Dilek
Background: The transmembrane receptor tyrosine kinase-like orphan receptor 1 (ROR1) has acted on the causation and sustentation of mature B-cell lymphomagenesis for chronic lymphocytic leukemia (CLL) cells. The study attempted to show whether there is a relationship between the level of ROR1 surface expression in CLL cells and disease findings. Materials and Methods: The level of ROR1 cell surface expression was determined in accordance with the flow cytometric analysis of CLL patients at the first diagnosis time...
January 1, 2023: International Journal of Hematology-oncology and Stem Cell Research
#37
REVIEW
Greta Maria Paola Giordano Attianese, Sarah Ash, Melita Irving
Adoptive T-cell transfer (ACT) therapies, including of tumor infiltrating lymphocytes (TILs) and T cells gene-modified to express either a T cell receptor (TCR) or a chimeric antigen receptor (CAR), have demonstrated clinical efficacy for a proportion of patients and cancer-types. The field of ACT has been driven forward by the clinical success of CD19-CAR therapy against various advanced B-cell malignancies, including curative responses for some leukemia patients. However, relapse remains problematic, in particular for lymphoma...
August 7, 2023: Immunological Reviews
#38
JOURNAL ARTICLE
Jingjing Jiao, Ksenia Chezar, Xuefeng Zhang, Donghai Wang, Wenqing Cao, Challa Bindu, Wei Chen, Antonio Galvao Neto, Patrick Henn, Irene Riahi, Hanlin L Wang, David J Papke, Lei Zhao, Yue Xue, Xiaoyan Liao, Xuchen Zhang
Postinfantile giant cell hepatitis (PIGCH) is a rare hepatitis pattern in adults with variable etiologies and clinical outcomes. We conducted a multi-institutional retrospective study to define the clinicopathologic characteristics of patients with PIGCH. A total of 70 PIGCH cases were identified and reviewed for pathological features, including fibrosis, cholestasis, inflammation, steatosis, necrosis, and apoptosis, as well as the distribution of giant cells and the maximum number of giant cells per high-power field...
August 6, 2023: Modern Pathology
#39
JOURNAL ARTICLE
María José Mela Osorio, Carolina Pavlovsky, Miguel Arturo Pavlovsky
Health equity is today an important objective to evenly reach the population among different health care systems. This article will focus on diagnosis and treatment access inequalities in Argentina. Although different aspects must be optimized to overcome access barriers worldwide, access inequalities in some regions of Argentina may depend basically on the type of health coverage or insurance. Health care in Argentina is divided into Public, Social security and Private care systems. Access to diagnosis and disease monitoring will vary according whether the patient is under each of these systems...
July 15, 2023: Seminars in Hematology
#40
JOURNAL ARTICLE
Natacha Rodrigues, Mariana Fragão-Marques, Cláudia Costa, Carolina Branco, Filipe Marques, Pedro Vasconcelos, Carlos Martins, Adelino Leite-Moreira, José António Lopes
Hematopoietic stem cell transplant (HSCT) is an important treatment option for hematologic malignancies. Acute kidney injury (AKI) is a common complication in HSCTs and is related to worse outcomes. We aimed to create a predictive risk score for AKI in HSCT considering variables available at the time of the transplant. We performed a retrospective cohort study. AKI was defined by the KDIGO classification using creatinine and urinary output criteria. We used survival analysis with competing events. Continuous variables were dichotomized according to the Liu index...
July 22, 2023: Cancers
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
